Evidence map›Paper›PMID 40256633›Full record

ArticleRheumatology advances in practice2025

Disease burden in inflammatory arthritis: an unsupervised machine learning approach of the COVAD-2 e-survey dataset.

Vincenzo Venerito, Sergio Del Vescovo, Sergio Prieto-González, Marco Fornaro, Lorenzo Cavagna, Florenzo Iannone, Masataka Kuwana, Vishwesh Agarwal, Jessica Day, Mrudula Joshi and 17 more

Abstract read
In one paragraph

Article in Rheumatology advances in practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. UK Medical Cannabis Registry: An Updated Analysis of Inflammatory Arthritis.Clinical medicine insights. Arthritis and musculoskeletal disorders · 2026
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Vincenzo VeneritoDepartment of Precision and Regenerative Medicine and Ionian Area (DiMePre-J), University of Bari Aldo Moro, Bari, Italy.ORCID https://orcid.org/0000-0002-2573-5930
Sergio Del VescovoDepartment of Precision and Regenerative Medicine and Ionian Area (DiMePre-J), University of Bari Aldo Moro, Bari, Italy.
Sergio Prieto-GonzálezDepartment of Internal Medicine, Hospital Clinic de Barcelona, Barcelona, Spain.ORCID https://orcid.org/0000-0003-3179-597X
Marco FornaroDepartment of Precision and Regenerative Medicine and Ionian Area (DiMePre-J), University of Bari Aldo Moro, Bari, Italy.ORCID https://orcid.org/0000-0003-1716-7432
Lorenzo CavagnaDivision of Rheumatology, Faculty of Medicine and Surgery, University of Pavia, Pavia, Italy.
Florenzo IannoneDepartment of Precision and Regenerative Medicine and Ionian Area (DiMePre-J), University of Bari Aldo Moro, Bari, Italy.ORCID https://orcid.org/0000-0003-0474-5344
Masataka KuwanaDepartment of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan.ORCID https://orcid.org/0000-0001-8352-6136
Vishwesh AgarwalMahatma Gandhi Mission Medical College, Maharashtra, India.
Jessica DayClinical Translation, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.ORCID https://orcid.org/0000-0001-8528-4361
Mrudula JoshiByramjee Jeejeebhoy Government Medical College and Sassoon General Hospitals, Pune, India.
Sreoshy SahaMymensingh Medical College, Mymensingh, Bangladesh.
Kshitij JagtapSeth Gordhandas Sunderdas Medical College, Mumbai, India.
Wanruchada KatchamartDivision of Rheumatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Phonpen Akarawatcharangura GooDepartment of Medicine, Queen Savang Vadhana Memorial Hospital, Chonburi, Thailand.
Binit VaidyaDepartment of Rheumatology, National Centre for Rheumatic Diseases, Kathmandu, Nepal.
Tsvetelina VelikovaMedical Faculty, Sofia University St. Kliment Ohridski, Sofia, Bulgaria.
Parikshit SenMaulana Azad Medical College, New Delhi, India.
Samuel Katsuyuki ShinjoDepartment of Rheumatology, Faculdade de Medicina da, Universidade de São Paulo, São Paulo, Brazil.ORCID https://orcid.org/0000-0002-3682-4517
Ai Lyn TanLeeds Institute of Rheumatic and Musculoskeletal Medicine and Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, UK.ORCID https://orcid.org/0000-0002-9158-7243
Nelly ZiadeRheumatology Department, Saint-Joseph University, Beirut, Lebanon.ORCID https://orcid.org/0000-0002-4479-7678
Marcin MilchertDepartment of Rheumatology, Pomorski Uniwersytet Medyczny w Szczecinie, Szczecin, Poland.ORCID https://orcid.org/0000-0002-0943-8768
Abraham Edgar Gracia-RamosDepartment of Internal Medicine, General Hospital, National Medical Center "La Raza", Instituto Mexicano del Seguro Social Delegacion Distrito Federal Norte, Mexico City, Mexico.ORCID https://orcid.org/0000-0003-1842-2554
Carlo V Caballero-UribeDepartment of Medicine, Hospital Universidad del Norte, Barranquilla, Colombia.
COVAD Study
Hector ChinoyDivision of Musculoskeletal and Dermatological Sciences, Centre for Musculoskeletal Research, School of Biological Sciences, The University of Manchester, Manchester, UK.ORCID https://orcid.org/0000-0001-6492-1288
Latika GuptaDivision of Musculoskeletal and Dermatological Sciences, Centre for Musculoskeletal Research, School of Biological Sciences, The University of Manchester, Manchester, UK.ORCID https://orcid.org/0000-0003-2753-2990
Vikas AgarwalDepartment of Clinical Immunology and Rheumatology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: To comprehensively compare the disease burden among patients with RA, PsA and AS using Patient-Reported Outcome Measurement Information System (PROMIS) scores and to identify distinct patient clusters based on comorbidity profiles and PROMIS outcomes. Methods: Data from the global COVID-19 Vaccination in Autoimmune Diseases (COVAD) 2 e-survey were analysed. Patients with RA, PsA or AS undergoing treatment with DMARDs were included. PROMIS scores (global physical health, global mental health, fatigue 4a and physical function short form 10a), comorbidities and other variables were compared among the three groups, stratified by disease activity status. Unsupervised hierarchical clustering with eXtreme Gradient Boosting feature importance analysis was performed to identify patient subgroups based on comorbidity profiles and PROMIS outcomes. Results: The study included 2561 patients (1907 RA, 311 PsA, 343 AS). After adjusting for demographic factors, no significant differences in PROMIS scores were observed among the three groups, regardless of disease activity status. Clustering analysis identified four distinct patient groups: low burden, comorbid PsA/AS, low burden with depression and high-burden RA. Feature importance analysis revealed PROMIS global physical health as the strongest determinant of cluster assignment, followed by depression and diagnosis. The comorbid PsA/AS and high-burden RA clusters showed a higher prevalence of comorbidities (56.47% and 69.7%, respectively) and depression (41.18% and 41.67%, respectively), along with poorer PROMIS outcomes. Conclusion: Disease burden in inflammatory arthritis is determined by a complex interplay of factors, with physical health status and depression playing crucial roles. The identification of distinct patient clusters suggests the need for a paradigm shift towards more integrated care approaches that equally emphasize physical and mental health, regardless of the underlying diagnosis.

Indexed as

cluster analysiscomorbiditiesdisease burdeninflammatory arthritismental healthpatient reported outcomePROMIS (Patient-Reported Outcome Measurement Information System)rheumatoid arthritisspondyloarthritissurvey

Identifiers

PMID40256633
PMCPMC12007600

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.